Work

EXTH-54 FLASH radiation reprograms tumor associated myeloid cells and spares circulating antigen-reactive CD8+ T-cells in mouse glioblastoma

Year: 2026
Type: article
Abstract: Glioblastoma is a highly lethal brain tumor with limited response to current therapies, including surgery, chemotherapy, and conventional radiation therapy (CONV-RT). Although CONV-RT stimulates tumor antigen release, it is associated with immunosuppression and neurotoxicity. Ultrahigh-dose-rate radiotherapy (FLASH-RT), which delivers radiation at more than 40Gy/second, maintains tumor control with minimal normal tissue damage or immunosuppression across multiple cancer types. Using a syngeneic GL261 glioblastoma-bearing mouse model, we evaluated the effects of FLASH-RT and CONV-RT. We hypothesized that FLASH-RT would be as effective as, or more effective than, CONV-RT for tumor control and would result in less immunosuppression within the tumor and systemically. We stereotactically implanted 2 × 105 mouse GL261 cells into the right forebrain of C57BL/6 mice. Five days after tumor initiation, tumor bearing mice were treated with Sham-RT (control), CONV-RT (mean dose rate > 0.373 Gy/s, 10 Gy total), or FLASH-RT (mean dose rate >3.6x106 Gy/s, 10 Gy total). Brain tumor tissue and peripheral blood were collected on days 5 and 12 after treatment. To assess changes in the tumor microenvironment and in circulation after CONV-RT or FLASH-RT, we performed 10x Genomics Xenium spatial transcriptomics, Lunaphore COMET multiplexed immunofluorescence, and flow cytometry. We also evaluated survival outcomes following treatment. Both FLASH-RT and CONV-RT improved survival compared to Sham-RT (P < 0.01), but FLASH-RT cured 50% of mice and improved survival more than CONV-RT. Compared to CONV-RT, FLASH-RT treatment markedly induced intratumoral infiltration of CD8+ T-cells, and preserved circulating PD-1+CD8+ T-cells, a key antigen-reactive cytotoxic T-cell population (P < 0.01). FLASH-RT also downregulated pro-tumoral M2-like genes (Arg1, Pd-l1, Ccl2) in tumor-associated macrophages (TAMs; Trem+ microglia and CD163+ peripheral macrophages). FLASH-RT is associated with better tumor control in mouse GL261 glioblastoma, less systemic immunosuppression, and may synergize better with immune checkpoint inhibitors to re-invigorate anti-tumor T-cell responses against glioblastoma.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7226007564
FWCI:
Cites:
Cited by:
Related to: 10